Page 99 - Read Online

Owusu Obeng et al. J Transl Genet Genom 2021;5:64-79 I http://dx.doi.org/10.20517/jtgg.2020.52 Page 77

the Clinical Pharmacogenetics Implementation Consortium (CPIC). J Am Med Inform Assoc 2016;23:796-801.
6. Swen JJ, Nijenhuis M, de Boer A, et al. Pharmacogenetics: from bench to byte--an update of guidelines. Clin Pharmacol Ther
2011;89:662-73.
7. Manolio TA, Rowley R, Williams MS, et al. Opportunities, resources, and techniques for implementing genomics in clinical care. Lancet
2019;394:511-20.
8. Peterson JF, Field JR, Shi Y, et al. Attitudes of clinicians following large-scale pharmacogenomics implementation. Pharmacogenomics J
2016;16:393-8.
9. Frigon MP, Blackburn MÈ, Dubois-Bouchard C, Gagnon AL, Tardif S, Tremblay K. Pharmacogenetic testing in primary care practice:
opinions of physicians, pharmacists and patients. Pharmacogenomics 2019;20:589-98.
10. FDA, U. Table of Pharmacogenetic Associations. Available from: https://www.fda.gov/medical-devices/precision-medicine/table-
pharmacogenetic-associations. [Last accessed on 16 Dec 2020]
11. Schackman BR, Scott CA, Walensky RP, Losina E, Freedberg KA, Sax PE. The cost-effectiveness of HLA-B*5701 genetic screening to
guide initial antiretroviral therapy for HIV. AIDS 2008;22:2025-33.
12. Plumpton CO, Pirmohamed M, Hughes DA. Cost-Effectiveness of Panel Tests for Multiple Pharmacogenes Associated With Adverse
Drug Reactions: An Evaluation Framework. Clin Pharmacol Ther 2019;105:1429-38.
13. Choi H, Mohit B. Cost-effectiveness of screening for HLA-B*1502 prior to initiation of carbamazepine in epilepsy patients of Asian
ancestry in the United States. Epilepsia 2019;60:1472-81.
14. Vo TT, Bell GC, Owusu Obeng A, Hicks JK, Dunnenberger HM. Pharmacogenomics Implementation: Considerations for Selecting a
Reference Laboratory. Pharmacotherapy 2017;37:1014-22.
15. Bousman CA, Zierhut H, Müller DJ. Navigating the Labyrinth of Pharmacogenetic Testing: A Guide to Test Selection. Clin Pharmacol
Ther 2019;106:309-12.
16. Pratt VM, Del Tredici AL, Hachad H, et al. Recommendations for Clinical CYP2C19 Genotyping Allele Selection: A Report of the
Association for Molecular Pathology. J Mol Diagn 2018;20:269-76.
17. Pratt VM, Cavallari LH, Del Tredici AL, et al. Recommendations for Clinical CYP2C9 Genotyping Allele Selection: A Joint
Recommendation of the Association for Molecular Pathology and College of American Pathologists. J Mol Diagn 2019;21:746-55.
18. Rescission of Guidances and Other Informal Issuances Concerning Premarket Review of Laboratory Developed Tests. Available from:
https://www.hhs.gov/coronavirus/testing/recission-guidances-informal-issuances-premarket-review-lab-tests/index.html. [Last accessed
on 16 Dec 2020]
19. de Leon J. Have we successfully implemented CYP2D6 genotyping in psychiatry? Expert Opin Drug Metab Toxicol 2017;13:1201-3.
20. Bousman C, Maruf AA, Müller DJ. Towards the integration of pharmacogenetics in psychiatry: a minimum, evidence-based genetic
testing panel. Curr Opin Psychiatry 2019;32:7-15.
21. Arwood MJ, Chumnumwat S, Cavallari LH, Nutescu EA, Duarte JD. Implementing Pharmacogenomics at Your Institution: Establishment
and Overcoming Implementation Challenges. Clin Transl Sci 2016;9:233-45.
22. Warning Letter Inova Genomics Laboratory. Available from: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-
investigations/warning-letters/inova-genomics-laboratory-577422-04042019. [Last accessed on 16 Dec 2020]
23. FDA Stepping Up Actions Against PGx Testing, Forcing Some Labs to Stop Reporting Drug Information. Available from: https://
www.360dx.com/regulatory-news-fda-approvals/fda-stepping-actions-against-pgx-testing-forcing-some-labs-stop#.X7Kz8ZNKjRY. [Last
accessed on 16 Dec 2020]
24. Roden DM, Van Driest SL, Mosley JD, et al. Benefit of Preemptive Pharmacogenetic Information on Clinical Outcome. Clin Pharmacol
Ther 2018;103:787-94.
25. El Rouby N, Alrwisan A, Langaee T, et al. Clinical Utility of Pharmacogene Panel-Based Testing in Patients Undergoing Percutaneous
Coronary Intervention. Clin Transl Sci 2020;13:473-81.
26. Dunnenberger HM, Crews KR, Hoffman JM, et al. Preemptive clinical pharmacogenetics implementation: current programs in five US
medical centers. Annu Rev Pharmacol Toxicol 2015;55:89-106.
27. Manolio TA, Chisholm RL, Ozenberger B, et al. Implementing genomic medicine in the clinic: the future is here. Genet Med
2013;15:258-67.
28. Cicali EJ, Weitzel KW, Elsey AR, et al. Challenges and lessons learned from clinical pharmacogenetic implementation of multiple gene-
drug pairs across ambulatory care settings. Genet Med 2019;21:2264-74.
29. Cavallari LH, Weitzel KW, Elsey AR, et al. Institutional profile: University of Florida Health Personalized Medicine Program.
Pharmacogenomics 2017;18:421-6.
30. Hoffman JM, Haidar CE, Wilkinson MR, et al. PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics. Am
J Med Genet C Semin Med Genet 2014;166C:45-55.
31. Bielinski SJ, Olson JE, Pathak J, et al. Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-
using genomic data to individualize treatment protocol. Mayo Clin Proc 2014;89:25-33.
32. Van Driest SL, Shi Y, Bowton EA, et al. Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic
testing. Clin Pharmacol Ther 2014;95:423-31.
33. Bielinski SJ, St Sauver JL, Olson JE, et al. Cohort Profile: The Right Drug, Right Dose, Right Time: Using Genomic Data to Individualize
Treatment Protocol (RIGHT Protocol). Int J Epidemiol 2020;49:23-24k.
34. Rosenman MB, Decker B, Levy KD, Holmes AM, Pratt VM, Eadon MT. Lessons Learned When Introducing Pharmacogenomic Panel
Testing into Clinical Practice. Value Health 2017;20:54-9.